Dermapharm Holding SE posts strong results for Q3 2024, Arkopharma (France) back above prior-year EBITDA levels for first time   Consolidated revenue up 2.7% to EUR 890.1 million. Growth in high-margin "Branded pharmaceuticals" more than offsets declining revenue in "Other healthcare products" segment. Above-average increase in (unadjusted) cons [ … ]

Dermapharm Holding SE: High-margin existing business in branded pharmaceuticals segment drives organic growth at German and international companies   Impressive organic growth in existing branded pharmaceuticals business at German and international companies compensates for drop in revenue due to scheduled end of pandemic-related boom in vaccine [ … ]

Dermapharm Holding SE: Sustained organic growth in high- margin existing branded pharmaceutical business   Strong organic growth of existing branded pharmaceutical business across virtually every market compensates for effects from scheduled end of pandemic phase in vaccine cooperation Consolidated revenue and (adjusted) EBITDA thus drop slightl [ … ]

Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share   2024 outlook confirmed Board of Management and Supervisory Board actions ratified with large majority Shareholders resolve dividend payment of EUR 0.88 per share Distribution ratio: approximately 78% of consolidated net profit   Grünwald, 27 J [ … ]

Strong organic growth in core marketsunderscores resilience of Dermapharm Holding SE's corporate strategy    Robust, double-digit organic growth in high-margin "branded pharmaceuticals" largely offsets projected decline in vaccine production. Revenue in "Other healthcare products" segment down year on year due to temporary consumer reticence, pa [ … ]

Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges   » Consolidated revenue up year on year by 10.8% to EUR 1,135.4 million » Adjusted consolidated EBITDA declines 13.8% to EUR 310.2 million » Adjusted consolidated EBITDA margin at 27.3% » Earnings decline as boom from vaccine business fades » Dividend p [ … ]

Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business     » Consolidated revenue up 10.8% year on year to EUR 1,135.4 million » Adjusted consolidated EBITDA declines by 13.8% to EUR 310.2 million » Adjusted consolidated EBITDA margin: 27.3% » Bo [ … ]